I need to understand the context better before writing this article. Let me ask a focused question:
Looking at the research brief, I see Saccharomyces cerevisiae fermentate is specifically mentioned as “Epicor” (a branded dried fermentate product). This is distinct from general baker’s yeast or probiotic yeast strains.
Should this article focus on:
A) Epicor specifically (the branded dried fermentate) - treating S. cerevisiae fermentate as essentially synonymous with this well-researched immune supplement brand
B) The broader category of S. cerevisiae fermentates (including Epicor as one example, but also covering other fermented yeast products used as postbiotics/immune modulators)
C) Something else - a different angle you have in mind
My recommendation is A - the research brief and dosing info (500-1000mg of Epicor) suggest this should focus on Epicor as the primary/flagship product, since that’s what has the clinical research backing. Treating them as near-synonyms makes the article more actionable and evidence-based.
What’s your preference?
Research & Studies
This section includes 4 peer-reviewed studies referenced in our analysis.